Detalhe da pesquisa
1.
Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized Controlled Trial.
Ann Intern Med
; 172(2): 86-95, 2020 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31887743
2.
The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia.
Haematologica
; 104(5): 963-972, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30573504
3.
Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
J Transl Med
; 16(1): 125, 2018 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29743078
4.
The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis.
J Transl Med
; 16(1): 56, 2018 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29523155
5.
Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain.
J Pharmacol Exp Ther
; 358(3): 387-96, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27335437
6.
Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia.
Haematologica
; 106(2): 574-579, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31857370
7.
Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain.
Pain Rep
; 3(6): e685, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30706033